NVIDIA
NVDA
Meta Platforms
META
Oracle
ORCL
Apple
AAPL
Alphabet-A
GOOGL
US Stock MarketDetailed Quotes
TCRX TScan Therapeutics
- 3.000
- +0.030+1.01%
Trading Dec 18 14:25 ET
160.11MMarket Cap-3.16P/E (TTM)
3.100High2.960Low221.62KVolume3.020Open2.970Pre Close665.52KTurnover0.69%Turnover RatioLossP/E (Static)53.37MShares9.69052wk High0.70P/B96.84MFloat Cap2.60052wk Low--Dividend TTM32.28MShs Float14.710Historical High--Div YieldTTM4.71%Amplitude1.450Historical Low3.002Avg Price1Lot Size
TScan Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -448.24%-27.92M | -19.09%-26.23M | -24.08%-29.27M | 7.74%-61.36M | -48.44%-23.77M | 147.15%8.02M | -64.75%-22.02M | -17.21%-23.59M | -36.62%-66.5M | -11.34%-16.01M |
| Net income from continuing operations | -29.96%-29.89M | -31.67%-31.66M | -33.59%-30.14M | -34.73%-89.22M | -4.75%-19.61M | -41.56%-23M | -59.27%-24.05M | -39.66%-22.56M | -36.19%-66.22M | -31.85%-18.72M |
| Depreciation and amortization | -20.14%1.03M | -13.89%1.12M | -16.34%1.25M | 4.36%5.36M | -13.75%1.28M | 2.80%1.29M | 7.37%1.3M | 25.44%1.5M | 54.36%5.14M | 29.95%1.48M |
| Other non cash items | -10.76%199K | -7.34%202K | -7.01%199K | 191.15%757K | -52.78%102K | --223K | --218K | --214K | --260K | --216K |
| Change In working capital | -100.98%-279K | 407.03%2.18M | 45.70%-2.11M | 272.10%17.61M | -2,082.39%-6.2M | 961.10%28.4M | -41.92%-711K | 36.81%-3.88M | -73.51%-10.23M | 86.51%-284K |
| -Change in prepaid assets | -68.88%-1.17M | -100.52%-15K | 121.61%255K | 340.24%985K | -102.46%-49K | 53.86%-694K | 140.33%2.91M | 43.97%-1.18M | 84.20%-410K | 350.23%1.99M |
| -Change in payables and accrued expense | 107.21%1.55M | 103.57%2.34M | -263.31%-2.01M | 201.67%3.8M | -61.43%670K | 56.69%749K | 13.08%1.15M | 162.47%1.23M | -61.16%1.26M | 382.44%1.74M |
| -Change in other working capital | 81.60%-659K | -100.53%-143K | 91.06%-352K | 215.70%12.82M | -70.01%-6.82M | -57.66%-3.58M | 1,095.49%27.16M | -90.24%-3.94M | -69.29%-11.08M | -107.50%-4.01M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -448.24%-27.92M | -19.09%-26.23M | -24.08%-29.27M | 7.74%-61.36M | -48.44%-23.77M | 147.15%8.02M | -64.75%-22.02M | -17.21%-23.59M | -36.62%-66.5M | -11.34%-16.01M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -34.09%-82.35M | -7,927.62%-33.72M | 4,415.39%36.16M | -1,338.08%-60.76M | 238.93%1.91M | -14,384.43%-61.41M | 77.81%-420K | -57.82%-838K | 57.50%-4.23M | 37.72%-1.38M |
| Net PPE purchase and sale | 3.45%-1.37M | -105.24%-862K | 15.87%-705K | 25.54%-3.15M | 65.94%-469K | -234.67%-1.42M | 77.81%-420K | -57.82%-838K | 57.50%-4.23M | 37.72%-1.38M |
| Net investment purchase and sale | -34.98%-80.98M | ---32.85M | --36.87M | ---57.61M | --2.38M | ---60M | --0 | --0 | --0 | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -34.09%-82.35M | -7,927.62%-33.72M | 4,415.39%36.16M | -1,338.08%-60.76M | 238.93%1.91M | -14,384.43%-61.41M | 77.81%-420K | -57.82%-838K | 57.50%-4.23M | 37.72%-1.38M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 588.10%1.23M | 19.10%161.59M | 258K | 361.38%135.44M | -82.41%19K | -100.87%-252K | 437,564.52%135.68M | 0 | -84.52%29.36M | -10.00%108K |
| Net issuance payments of debt | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --29.35M | --0 |
| Net common stock issuance | --0 | ---- | ---- | 21,876.17%42.41M | --0 | ---186K | ---- | ---- | -99.78%193K | --193K |
| Proceeds from stock option exercised by employees | 1,963.64%1.23M | 38.01%128.46M | --258K | 69,846.62%93.03M | 111.11%19K | -1,420.00%-66K | 300,145.16%93.08M | --0 | -54.30%133K | -92.50%9K |
| Net other financing activities | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---324K | ---94K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 588.10%1.23M | 19.10%161.59M | --258K | 361.38%135.44M | -82.41%19K | -100.87%-252K | 437,564.52%135.68M | --0 | -84.52%29.36M | -10.00%108K |
| Net cash flow | ||||||||||
| Beginning cash position | 15.58%247.19M | 44.62%145.54M | 10.66%138.39M | -24.86%125.06M | 12.56%160.22M | 63.71%213.87M | -31.01%100.64M | -24.86%125.06M | 370.34%166.44M | -22.18%142.34M |
| Current changes in cash | -103.25%-109.04M | -10.23%101.65M | 129.29%7.15M | 132.21%13.33M | -26.36%-21.83M | -558.42%-53.65M | 843.54%113.23M | -18.76%-24.43M | -131.57%-41.37M | -4.91%-17.28M |
| End cash Position | -13.78%138.15M | 15.58%247.19M | 44.62%145.54M | 10.66%138.39M | 10.66%138.39M | 12.56%160.22M | 63.71%213.87M | -31.01%100.64M | -24.86%125.06M | -24.86%125.06M |
| Free cash flow | -543.89%-29.29M | -20.70%-27.09M | -22.71%-29.97M | 8.80%-64.5M | -39.39%-24.24M | 137.86%6.6M | -47.06%-22.44M | -18.25%-24.43M | -20.66%-70.73M | -4.80%-17.39M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.